NLRP3 and cardiac hypertrophy: The expression of NLRP3/IL-1β/caspase-1 has been observed in patients with diabetes, myocardial infarction, arrhythmia, and cardiac hypertrophy, and some agents can improve the symptoms of cardiovascular disease in patients by inhibiting the occurrence of pyroptosis.